1. Home
  2. MDGL vs VIST Comparison

MDGL vs VIST Comparison

Compare MDGL & VIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • VIST
  • Stock Information
  • Founded
  • MDGL 2011
  • VIST 2017
  • Country
  • MDGL United States
  • VIST Mexico
  • Employees
  • MDGL N/A
  • VIST N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • VIST Oil & Gas Production
  • Sector
  • MDGL Health Care
  • VIST Energy
  • Exchange
  • MDGL Nasdaq
  • VIST Nasdaq
  • Market Cap
  • MDGL 6.1B
  • VIST 5.1B
  • IPO Year
  • MDGL N/A
  • VIST 2019
  • Fundamental
  • Price
  • MDGL $440.75
  • VIST $34.75
  • Analyst Decision
  • MDGL Strong Buy
  • VIST Strong Buy
  • Analyst Count
  • MDGL 10
  • VIST 4
  • Target Price
  • MDGL $474.67
  • VIST $65.75
  • AVG Volume (30 Days)
  • MDGL 341.0K
  • VIST 1.3M
  • Earning Date
  • MDGL 10-30-2025
  • VIST 10-22-2025
  • Dividend Yield
  • MDGL N/A
  • VIST N/A
  • EPS Growth
  • MDGL N/A
  • VIST 26.19
  • EPS
  • MDGL N/A
  • VIST 5.47
  • Revenue
  • MDGL $515,547,000.00
  • VIST $1,982,699,000.00
  • Revenue This Year
  • MDGL $394.12
  • VIST $38.98
  • Revenue Next Year
  • MDGL $57.74
  • VIST $18.03
  • P/E Ratio
  • MDGL N/A
  • VIST $6.61
  • Revenue Growth
  • MDGL 3421.98
  • VIST 49.52
  • 52 Week Low
  • MDGL $200.63
  • VIST $31.63
  • 52 Week High
  • MDGL $457.16
  • VIST $61.67
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 62.88
  • VIST 35.02
  • Support Level
  • MDGL $415.53
  • VIST $35.32
  • Resistance Level
  • MDGL $440.90
  • VIST $37.25
  • Average True Range (ATR)
  • MDGL 14.27
  • VIST 1.63
  • MACD
  • MDGL -4.71
  • VIST -0.01
  • Stochastic Oscillator
  • MDGL 60.58
  • VIST 38.27

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About VIST Vista Energy S.A.B. de C.V. each representing one series A share with no par value

Vista Energy SAB de CV is an independent oil and gas company. It is focused on shale oil and shale gas exploration at its main assets in Vaca Muerta. The company has operations in Argentina and Mexico. The company operates in a single segment- the exploration and production of Crude oil, Natural gas, and LPG. Geographically, It operates in Argentina and Mexico. it generates the majority of its revenue from Argentina.

Share on Social Networks: